Status of hydroxychloroquine: COVID disease management protocol

Abstract

Hydroxychloroquine, a safe derivative of chloroquine has been in practice since 1950. This drug has been used successfully as anti-viral agent previously. Its role in COVID-2 has been authenticated in the management protocol. The sudden death assigned to hydroxychloroquine is misplaced though it can be a very uncommon complication in cardiac patients with arrhythmia. Its prophylactic and therapeutic dose schedule needs to be streamlined at a lower dose schedule and is recommended to be used in early part of the disease and not during the stage of later complication. Keywords: Hydroxychloroquine, Arrhythmia, Pathogen, Host target cell, ACE-2, Intracellular.